Tarık Ercan

Tarık Ercan

Auto-generated profile, based on publicly available information

Tarık Ercan

Division of Hematology, Department of Internal Medicine Bahçeşehir University Faculty of Medicine Istanbul Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Turkish Journal of Hematology
Verified
Journal Article
Open access
ZÖZehra Narlı Özdemir
Zehra Narlı Özdemir
YIYildiz Ipek
Yildiz Ipek
PPPusem Patir
Pusem Patir
GEGözde Ermiş
Gözde Ermiş
RÇRafiye Çiftçiler
Rafiye Çiftçiler
AEAhmet Emre Eskazan
Ahmet Emre Eskazan
Objective: In this study, we investigated the effects of calreticulin (CALR) and JAK2V617F mutational status on clinical course and disease outcomes in Turkish patients with essential thrombocythemia (ET). Materials and Methods: Seventeen centers from Turkiye participated in the study and CALR- and JAK2V617F-mutated ET patients were evaluated retrospectively. Results: A total of 302 patients were included, of whom 203 (67.2%) and 99 (32.8%) were JAK2V617F- and CALR-positive, respectively. CALR-mutated patients were significantly younger (51 years vs. 57.5 years, p=0.03), with higher median platelet counts (987x109/L vs. 709x109/L, p<0.001) and lower median hemoglobin levels (13.1 g/dL vs. 14.1 g/dL, p<0.001) compared to JAK2V617F-mutated patients. Thromboembolic events (TEEs) occurred in 54 patients (17.9%), 77.8% of which were arterial. Compared to CALR mutation, JAK2V617F was associated with a higher risk of thrombosis (8.1% vs. 22.7%, p=0.002). Rates of transformation to myelofibrosis (MF) and leukemia were 4% and 0.7%, respectively, and these rates were comparable between JAK2V617F- and CALR-mutated cases. The estimated overall survival (OS) and MF-free survival of the entire cohort were 265.1 months and 235.7 months, respectively. OS and MF-free survival durations were similar between JAK2V617F- and CALR-mutated patients. Thrombosis -free survival (TFS) was superior in CALR-mutated patients compared to JAK2V617F-positive patients (5 -year TFS: 90% vs. 71%, respectively; p=0.001). Age at diagnosis was an independent factor affecting the incidence of TEEs. Conclusion: In our ET cohort, CALR mutations resulted in higher platelet counts and lower hemoglobin levels than JAK2V617F and were associated with younger age at diagnosis. JAK2V617F was strongly associated with thrombosis and worse TFS. Hydroxyurea was the most preferred cytoreductive agent for patients with high thrombosis risk.

31 December 2021 in Blood Research
Verified
Journal Article
Open access
PDF file
FAFatma Arikan
Fatma Arikan
TTTayfur Toptas
Tayfur Toptas
IAIsik Atagunduz
Isik Atagunduz
TETarik Ercan
Tarik Ercan
OOOzen Oruc
Ozen Oruc
TTTulin Tuglular
Tulin Tuglular
Fatma Arikan, Tayfur Toptas, Isik Kaygusuz Atagunduz, Tarik Ercan, Ozen Oruc, Fergun Yilmaz, Tulin Tuglular. Blood Res 2021;56:322-31. https://doi.org/10.5045/br.2021.2021101

17 August 2024 in Transfusion
Verified
Journal Article
Open access
SÖSıdıka Gülkan Özkan
Sıdıka Gülkan Özkan
AKAli Kimiaei
Ali Kimiaei
SSSeyedehtina Safaei
Seyedehtina Safaei
TETarık Ercan
Tarık Ercan
MSMeral Sönmezoğlu
Meral Sönmezoğlu
HÖHasan Atilla Özkan
Hasan Atilla Özkan
Background: Peripheral blood‐derived hematopoietic stem cells (HSCs) are widely used for various adult stem cell transplants. To obtain sufficient HSCs from healthy volunteer donors during the apheresis process and ensure that the donors are exposed to fewer apheresis‐related side effects, calculation methods have been developed for the prediction of processed blood volume or CD34+ count. However, there is no consensus on a formula to predict the volume of blood to be processed or the number of stem cells to be obtained.Objective: This study aimed to estimate the predicted blood volume and CD34+ cell counts using collection efficiency (CE)‐based formulas and evaluate their accuracy compared to the actual CD34+ cell counts. It also seeks to identify the factors that affect CE.Methods: Data from 397 healthy, unrelated stem cell donors were retrospectively analyzed. An algorithm using four different CE2 metrics (1st quartile, mean, 3rd quartile, and median) was developed to predict the volume of blood to be processed using the Spectra Optia continuous mononuclear cell collection procedure.Results: When employing the mean CE2 algorithm, the results revealed a strong correlation (r = .894, p < .001) between predicted and actual CD34+ values. The study also identified strong associations between pre‐apheresis CD34+, pre‐apheresis leukocyte count, the use of two doses of G‐CSF, and low CE2.Conclusion: These findings suggest that the mean CE2 algorithm could be a potent, straightforward, and accurate tool for predicting CD34+ stem cell counts in healthy allogeneic stem cell donors and potentially optimizing stem cell collection procedures.

13 November 2026 in Journal of Current Hematology & Oncology Research
Verified
Journal Article
Closed access
AYAsu Fergun Yilmaz
Asu Fergun Yilmaz
MMMeral ULUKOYLU MENGUC
Meral ULUKOYLU MENGUC
TETarık Ercan
Tarık Ercan
ABArda Bayar
Arda Bayar
CGCeren Uzunoğlu Güren
Ceren Uzunoğlu Güren
IAIsik Atagunduz
Isik Atagunduz
Aims: Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal lymphoma with generally favorable outcomes following anthracycline-based immunochemotherapy. However, the prognostic impact of disease distribution remains poorly defined, and only a limited number of studies have reported treatment outcomes separately for patients with unifocal (UF) and multifocal (MF) disease. This study aimed to evaluate the clinical characteristics, treatment outcomes, survival, and safety of PB-DLBCL, with particular emphasis on differences between UF and MF disease. Methods: This retrospective single-center study included 13 consecutive adult patients with histologically confirmed PB-DLBCL diagnosed between 2010 and 2025. Patients were classified as UF (n=9) or MF (n=4) according to the number of involved bone sites. Clinical characteristics, treatment response, survival outcomes, and treatment-related adverse events were analyzed. Results: The median age was 59 years (range, 18–78), and localized bone pain was the most common presenting symptom (92.3%). Patients with MF disease tended to present with more adverse clinical features, including bulky lesions, elevated lactate dehydrogenase levels, larger lesions, and poorer performance status. Complete and partial responses were achieved in 9 (69.2%) and 1 (7.7%) patient, respectively, yielding an overall response rate of 76.9%. The overall response rate was 100% in the UF group compared with 25% in the MF group (p=0.014). The median overall survival was 88.15 months, with a 2-year overall survival rate of 91.7%; the corresponding 2-year overall survival rates were 100% and 66.7% in the UF and MF groups, respectively. Hematologic toxicities were the most common adverse events, while grade 3–4 toxicities were infrequent and treatment was generally well tolerated. Conclusion: Anthracycline-based immunochemotherapy provides excellent outcomes for most patients with PB-DLBCL. However, MF disease is associated with substantially inferior treatment response and survival compared with UF disease. Despite the limited sample size, our findings add to the scarce literature evaluating UF and MF disease separately and further support disease distribution as an important prognostic factor in PB-DLBCL. Future multicenter studies are warranted to validate these findings and optimize treatment strategies for patients with MF disease.